Latest 3 stories · newest Nov 4, 2026
Acadia Pharmaceuticals beats Q3 expectations with $342M revenue, raising DAYBUE guidance to $505M-$520M and announcing a new patent extension and FDA Fast Track designation for remlifanserin in Lewy body dementia.
Acadia Healthcare Company Inc. has reached a settlement agreement with plaintiffs and defendants to resolve federal and state-level derivative lawsuits, with provisions continuing during its restructuring process.
Acadian Asset Management Inc. filed its 2026 Equity Incentive Plan to provide stock-based compensation to employees and subsidiaries. The plan is designed to encourage employee ownership and align incentives with company performance.
The same ACAD feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/ACAD/newsSTART FREE